Gf Fund Management Co. Ltd. C4 Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.62 Trillion
- Q4 2024
A detailed history of Gf Fund Management Co. Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,482 shares of CCCC stock, worth $4,460. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,482Holding current value
$4,460% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$21 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$20.6 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$18.3 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$14.7 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$13.7 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $147M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...